Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Aiforia Technologies

1.00 EUR+1.73 %4.9, 17.29
2,230 following

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

Overview
Financials & Estimates
Dividend
Investor views
Compare
+1.73 %
-15.99 %
-46.00 %
-39.52 %
-59.92 %
-64.98 %
-75.95 %
-
-80.28 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
37.31M EUR
Turnover
61.96K EUR
P/E (adj.) (26e)
-2.77
EV/EBIT (adj.) (26e)
-3.04
P/B (26e)
3.22
EV/S (26e)
15.1
Dividend yield-% (26e)
-
Coverage
Recommendation
Reduce
Target price
1.10 EUR
Updated
31.08.2026
Disclaimer
Antti Luiro
Antti Siltanen
Antti Siltanen, Antti Luiro
Show more
Latest research

Latest analysis report

Released: 31.08.2026

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%
EPS and dividend
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Aiforia out of the model portfolio. Apparently, the rise can now begin based on this old and tired thesis. I honestly don’t believe that a growth trajectory will be reached terribly quickly here, and based on the current performance, it’s probably not entirely wrong to wonder whether...
9/2/2026, 9:14 AM
by Jankkeri
17
Doctors as a professional group are the absolute last to want to do things differently. A completely set-in-their-ways professional group. The decision to adopt a new way of working has to come from the organization, the wellbeing services county (Hyvinvointialue) or similar, which...
8/31/2026, 12:52 PM
by 1sarvinen
15
Based on the published figures (including the order backlog), sales have been really modest over the past year. An attempt is being made to fix the situation by establishing a Customer Success unit and hiring a new Sales Director. The measures are logical in themselves, but the slowness...
9/1/2026, 10:15 AM
14
Aiforia has been named a top market player. The translation is from LinkedIn. The poster is a PR firm for a market research company. Such reports do not automatically carry the same level of reliability as the aforementioned scientific article in a decent-tier journal (even if it...
9/1/2026, 5:50 AM
by Vino Pino
14
It’s not called a model portfolio for nothing. In true retail investor fashion, after a long slide, an exit with a massive loss. Well, it’s pretty hard to see in this case where the commercial drivers are and whether the company will ever get back on its feet.
9/2/2026, 1:08 PM
12
It’s good that encouraging cost-benefit calculations are being done in scientific journals and that problems like the initial investment costs mentioned at the beginning are being recognized. Perhaps that initial cost is also eased by Aiforian’s smoothing of billing (which didn’t...
8/31/2026, 5:04 PM
by Vino Pino
11
Some might find this study, published early last year, interesting. It examines practical experiences with the implementation of digital pathology. While it covers the entire value chain, AI solutions are also touched upon under the term computational pathology. The study is openly...
8/31/2026, 11:53 AM
by Antti Siltanen
11
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Modelportfolio: Vi har ryddet ud i den mislykkede Aiforia-investering i porteføljen
Research02.09.2026, 09.00 by
Juha Kinnunen, Atte Riikola, Rauli Juva

Modelportfolio: Vi har ryddet ud i den mislykkede Aiforia-investering i porteføljen

I vores vækstinvestering med høj risiko udeblev væksten, hvilket ødelagde vores oprindelige investeringsteser.

Aiforia Technologies
Third party research02.09.2026, 08.08

Aiforia Technologies: H1'26 review: costs above expectations; est. & PT chg. - NuWays AG Research

Aiforia published its H1'26 report last Friday. Revenue of € 0.75m (-46% yoy) was already knownfrom the July profit warning, which we attributed to the absence of onboarding revenue and a slower than expected usage ramp up of existing clinical clients...

Aiforia Technologies
Aiforia H1'26: Still a long way to go before reaching profitability
Research31.08.2026, 13.26 by
Antti Siltanen, Antti Luiro

Aiforia H1'26: Still a long way to go before reaching profitability

Earnings fell short of our expectations due to both a one-off expense and a more permanent increase in the cost structure.

Aiforia Technologies

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Aiforia, Webcast, Q2'26
Webcast28.08.2026, 09.00

Aiforia, Webcast, Q2'26

Aiforia Technologies
Regulatory press release28.08.2026, 08.00

Aiforia’s Half-Year Financial Report January-June 2026: Financing arrangements and new customers support future growth, revenue remained below the comparison period's level

Aiforia Technologies
Aiforia lands new partnership in breast cancer diagnostics
Analyst Comment26.08.2026, 09.59 by
Antti Siltanen

Aiforia lands new partnership in breast cancer diagnostics

The new partnership brings predictive risk profiling into diagnostics and can reduce the need for expensive genetic tests.

Aiforia Technologies
Aiforia H1'26 preview: Profit warning increased concerns about commercial progress
Analyst Comment26.08.2026, 12.00 by
Antti Siltanen

Aiforia H1'26 preview: Profit warning increased concerns about commercial progress

Contract delays caused H1 revenue to collapse to 0.75 MEUR and increased concerns about commercial performance.

Aiforia Technologies
Press release25.08.2026, 08.30

Aiforia and Stratipath partner to expand access to AI-driven precision diagnostics in oncology

Aiforia Technologies
Press release19.08.2026, 07.00

Aiforia to publish January–June 2026 Half-Year Financial Report on August 28, 2026

Aiforia Technologies
Aiforia secured a 20 MEUR financing agreement with the EIB
Analyst Comment03.08.2026, 08.19 by
Antti Siltanen, Antti Luiro

Aiforia secured a 20 MEUR financing agreement with the EIB

The loan arrangement secures financing for the coming years, provided the business develops favorably.

Aiforia Technologies
Regulatory press release31.07.2026, 17.00

Aiforia and the European Investment Bank have signed an agreement for EUR 20 million venture debt financing

Aiforia Technologies
Regulatory press release24.07.2026, 10.00

Aiforia Technologies Plc – Managers’ Transactions – Jukka Tapaninen

Aiforia Technologies
Third party research23.07.2026, 09.04

Aiforia Technologies: Aiforia H1 profit warning triggers downgrade to HOLD - NuWays AG Research

Aiforia issued a profit warning with H1'26 revenues coming in at a mere € 0.75m, down from € 1.4m in H1'25 (-46% yoy), against our expectation of roughly doubling yoy, following last year's strong Clinical momentum (organic growth of +65%). At the same...

Aiforia Technologies
Aiforia: We diagnose a growth deficiency
Research23.07.2026, 09.25 by
Antti Siltanen

Aiforia: We diagnose a growth deficiency

The ongoing uncertainty regarding growth is causing us to take a negative view of the risk-reward ratio.

Aiforia Technologies
Aiforia's H1 revenue was surprisingly subdued
Analyst Comment22.07.2026, 08.05 by
Antti Siltanen

Aiforia's H1 revenue was surprisingly subdued

The conversion of customer wins into revenue continues to be slow.

Aiforia Technologies
Regulatory press release21.07.2026, 17.40

Inside information, profit warning: Aiforia's revenue developed below the estimates during January–June 2026

Aiforia Technologies
Regulatory press release06.07.2026, 08.00

Aiforia Technologies Plc – Managers’ Transactions – Tuomas Tenkanen

Aiforia Technologies
Regulatory press release06.07.2026, 08.00

Aiforia Technologies Plc – Managers’ Transactions – Johan Lundin

Aiforia Technologies
Regulatory press release01.07.2026, 20.00

Aiforia Technologies Plc: Disclosure under Chapter 9 Section 10 of the Securities Market Act (Acme Investments SPF Sarl)

Aiforia Technologies
Third party research29.06.2026, 09.21

Aiforia Technologies: € 6.4m share issue de-risks the investment case - NuWays AG Research

On Thursday evening, Aiforia announced having completed a directed share issue of 3.6m shares at € 1.772 per share, raising gross proceeds of some € 6.4m. The subscription price corresponds to the closing price of June 25th, representing no discount ...

Aiforia Technologies